Liquid biopsy technology is advancing, but investors remain sceptical.

Startups across Israel are developing liquid biopsy tests, and the quest for investment is growing ever more competitive. As a result, the need for companies in the field to differentiate their offering and clearly articulate how it functions is of increasing importance.

Read more here.